Predictive factors for acute radiation pneumonitis;Facteurs prédictifs de la pneumopathie radique aiguë

Revue de Pneumologie Clinique

Volumn 65, Issue 3, 2009, Pages 177-186

  Arpin, D ^a   Mahe M A ^b   Servois, V ^c   Claude, L ^d  

^a CROIX ROUSSE HOSPITAL   (France)

^b CENTRE RENÉ GAUDUCHEAU   (France)

^c INSTITUT CURIE   (France)

^d CENTRE LÉON BÉRARD   (France)

Author keywords

Cytokines; Non small cell lung cancer; Radiation pneumonitis

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA;

ACUTE DISEASE; CANCER RADIOTHERAPY; DISEASE SEVERITY; DOSIMETRY; HUMAN; INCIDENCE; LUNG NON SMALL CELL CANCER; LUNG VOLUME; PATHOGENESIS; RADIATION DOSE; RADIATION PNEUMONIA; REVIEW; RISK FACTOR;

ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; RADIATION PNEUMONITIS; RADIOTHERAPY DOSAGE; RISK FACTORS;

EID: 67649387952     PISSN: 07618417     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pneumo.2009.03.011     Document Type: Review

References (69)

1. Roach III M., Gandara D.R., Yuo H.S., Swift P.S., Kroll S., Shrieve D.C., et al. Radiation pneumonitis following combined modality therapy for lung cancer: analysis of prognostic factors. J Clin Oncol 13 (1995) 2606-2612
2. Arriagada R., Le Chevalier T., Quoix E., Ruffie P., de Cremoux H., Douillard J.Y., et al. ASTRO (American Society for Therapeutic Radiology and Oncology) plenary: effect of chemotherapy on locally advanced non-small cell lung carcinoma: a randomized study of 353 patients. GETCB (Groupe d'étude et traitement des cancers bronchiques), FNCLCC (Fédération nationale des centres de lutte contre le cancer) and the CEBI trialists. Int J Radiat Oncol Biol Phys 20 (1991) 1183-1190
3. Bradley J.D., Wahab S., Lockett M.A., Perez C.A., and Purdy J.A. Elective nodal failures are uncommon in medically inoperable patients with stage I non-small-cell lung carcinoma treated with limited radiotherapy fields. Int J Radiat Oncol Biol Phys 56 (2003) 342-347
4. Gauden S.J., and Tripcony L. The curative treatment by radiation therapy alone of stage I non-small cell lung cancer in a geriatric population. Lung Cancer 32 (2001) 71-79
5. Krol A.D., Aussems P., Noordijk E.M., Hermans J., and Leer J.W. Local irradiation alone for peripheral stage I lung cancer: could we omit the elective regional nodal irradiation?. Int J Radiat Oncol Biol Phys 34 (1996) 297-302
6. Morita K., Fuwa N., Suzuki Y., Nishio M., Sakai K., Tamaki Y., et al. Radical radiotherapy for medically inoperable non-small cell lung cancer in clinical stage I: a retrospective analysis of 149 patients. Radiother Oncol 42 (1997) 31-36
7. Sirzen F., Kjellen E., Sorenson S., and Cavallin-Stahl E. A systematic overview of radiation therapy effects in non-small cell lung cancer. Acta Oncol 42 (2003) 493-515
8. Saunders M., Dische S., Barrett A., Harvey A., Gibson D., and Parmar M. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee. Lancet 350 (1997) 161-165
9. Movsas B., Raffin T.A., Epstein A.H., and Link Jr. C.J. Pulmonary radiation injury. Chest 111 (1997) 1061-1076
10. Claude L., Perol D., Ginestet C., Falchero L., Arpin D., Vincent M., et al. A prospective study on radiation pneumonitis following conformal radiation therapy in non-small-cell lung cancer: clinical and dosimetric factors analysis. Radiother Oncol 71 (2004) 175-181
11. Byhardt R.W., Abrams R., and Almagro U. The association of adult respiratory distress syndrome (ARDS) with thoracic irradiation (RT). Int J Radiat Oncol Biol Phys 15 (1988) 1441-1446
12. Cottin V., Frognier R., Monnot H., Levy A., DeVuyst P., and Cordier J.F. Chronic eosinophilic pneumonia after radiation therapy for breast cancer. Eur Respir J 23 (2004) 9-13
13. De Jaeger K., Seppenwoolde Y., Boersma L.J., Muller S.H., Baas P., Belderbos J.S., et al. Pulmonary function following high-dose radiotherapy of non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 55 (2003) 1331-1340
14. Martin C., Romero S., Sanchez-Paya J., Massuti B., Arriero J.M., and Hernandez L. Bilateral lymphocytic alveolitis: a common reaction after unilateral thoracic irradiation. Eur Respir J 13 (1999) 727-732
15. Roberts C.M., Foulcher E., Zaunders J.J., Bryant D.H., Freund J., Cairns D., et al. Radiation pneumonitis: a possible lymphocyte-mediated hypersensitivity reaction. Ann Intern Med 118 (1993) 696-700
16. Nakayama Y., Makino S., Fukuda Y., Min K.Y., Shimizu A., and Ohsawa N. Activation of lavage lymphocytes in lung injuries caused by radiotherapy for lung cancer. Int J Radiat Oncol Biol Phys 34 (1996) 459-467
17. Kocak Z., Evans E.S., Zhou S.M., Miller K.L., Folz R.J., Shafman T.D., et al. Challenges in defining radiation pneumonitis in patients with lung cancer. Int J Radiat Oncol Biol Phys 62 (2005) 635-638
18. Graham M.V., Purdy J.A., Emami B., Matthews J.W., and Harms W.B. Preliminary results of a prospective trial using three dimensional radiotherapy for lung cancer. Int J Radiat Oncol Biol Phys 33 (1995) 993-1000
19. Monson J.M., Stark P., Reilly J.J., Sugarbaker D.J., Strauss G.M., Swanson S.J., et al. Clinical radiation pneumonitis and radiographic changes after thoracic radiation therapy for lung carcinoma. Cancer 82 (1998) 842-850
20. Denis F., Garaud P., Bardet E., Alfonsi M., Sire C., Germain T., et al. Late toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced-stage oropharynx carcinoma: comparison of LENT/SOMA, RTOG/EORTC, and NCI-CTC scoring systems. Int J Radiat Oncol Biol Phys 55 (2003) 93-98
21. Quon H., Shepherd F.A., Payne D.G., Coy P., Murray N., Feld R., et al. The influence of age on the delivery, tolerance, and efficacy of thoracic irradiation in the combined modality treatment of limited stage small cell lung cancer. Int J Radiat Oncol Biol Phys 43 (1999) 39-45
22. Robnett T.J., Machtay M., Vines E.F., McKenna M.G., Algazy K.M., and McKenna W.G. Factors predicting severe radiation pneumonitis in patients receiving definitive chemoradiation for lung cancer. Int J Radiat Oncol Biol Phys 48 (2000) 89-94
23. Graham M.V., Purdy J.A., Emami B., Harms W., Bosch W., Lockett M.A., et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 45 (1999) 323-329
24. Hernando M.L., Marks L.B., Bentel G.C., Zhou S.M., Hollis D., Das S.K., et al. Radiation induced pulmonary toxicity: a dose-volume histogram analysis in 201 patients with lung cancer. Int J Radiat Oncol Biol Phys 51 (2001) 650-659
25. Marks L.B., Munley M.T., Bentel G.C., Zhou S.M., Hollis D., Scarfone C., et al. Physical and biological predictors of changes in whole-lung function following thoracic irradiation. Int J Radiat Oncol Biol Phys 39 (1997) 563-570
26. Segawa Y., Takigawa N., Kataoka M., Takata I., Fujimoto N., and Ueoka H. Risk factors for development of radiation pneumonitis following radiation therapy with or without chemotherapy for lung cancer. Int J Radiat Oncol Biol Phys 39 (1997) 91-98
27. Yamada M., Kudoh S., Hirata K., Nakajima T., and Yoshikawa J. Risk factors of pneumonitis following chemoradiotherapy for lung cancer. Eur J Cancer 34 (1998) 71-75
28. Ohe Y., Yamamoto S., Suzuki K., Hojo F., Kakinuma R., Matsumoto T., et al. Risk factors of treatment-related death in chemotherapy and thoracic radiotherapy for lung cancer. Eur J Cancer 37 (2001) 54-63
29. Rancati T., Ceresoli G.L., Gagliardi G., Schipani S., and Cattaneo G.M. Factors predicting radiation pneumonitis in lung cancer patients: a retrospective study. Radiother Oncol 67 (2003) 275-283
30. Hanna Y.M., Baglan K.L., Stromberg J.S., Vicini F.A., and Decker A. Acute and subacute toxicity associated with concurrent adjuvant radiation therapy and paclitaxel in primary breast cancer therapy. Breast J 8 (2002) 149-153
31. Taghian A.G., Assaad S.I., Niemierko A., Kuter I., Younger J., Schoenthaler R., et al. Risk of pneumonitis in breast cancer patients treated with radiation therapy and combination chemotherapy with paclitaxel. J Natl Cancer Inst 93 (2001) 1806-1811
32. Pisch J., Moskovitz T., Esik O., Homel P., and Keller S. Concurrent paclitaxel-cisplatin and twice-a-day irradiation in stage IIIA and IIIB NSCLC shows improvement in local control and survival with acceptable hematologic toxicity. Pathol Oncol Res 8 (2002) 163-169
33. Onishi H., Kuriyama K., Yamaguchi M., Komiyama T., Tanaka S., Araki T., et al. Concurrent two-dimensional radiotherapy and weekly docetaxel in the treatment of stage III non-small cell lung cancer: a good local response but no good survival due to radiation pneumonitis. Lung Cancer 40 (2003) 79-84
34. Schaake-Koning C., van den B.W., Dalesio O., Festen J., Hoogenhout J., van Houtte P., et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 326 (1992) 524-530
35. Gandara D.R., Chansky K., Gaspar L.E., Albain K.S., Lara P.N., and Crowley J. Long term survival in stage IIIb non-small cell lung cancer (NSCLC) treated with consolidation docetaxel following concurrent chemoradiotherapy (SWOG S9504). Proc Am Soc Clin Oncol (2005) A 7059
36. Vokes E.E., Herndon J.E., Crawford J., Leopold K.A., Perry M.C., Miller A.A., et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol 20 (2002) 4191-4198
37. Fryer C.J., Fitzpatrick P.J., Rider W.D., and Poon P. Radiation pneumonitis: experience following a large single dose of radiation. Int J Radiat Oncol Biol Phys 4 (1978) 931-936
38. Libshitz H.I., and Southard M.E. Complications of radiation therapy: the thorax. Semin Roentgenol 9 (1974) 41-49
39. Geara F.B., Komaki R., Tucker S.L., Travis E.L., and Cox J.D. Factors influencing the development of lung fibrosis after chemoradiation for small cell carcinoma of the lung: evidence for inherent interindividual variation. In: Mornex F., and van Houtte P. (Eds). Treatment optimization for lung cancer: from classical to innovative procedures (1998) p. 139-150
40. Inoue A., Kunitoh H., Sekine I., Sumi M., Tokuuye K., and Saijo N. Radiation pneumonitis in lung cancer patients: a retrospective study of risk factors and the long-term prognosis. Int J Radiat Oncol Biol Phys 49 (2001) 649-655
41. Cox J.D., Azarnia N., Byhardt R.W., Shin K.H., Emami B., and Pajak T.F. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11. J Clin Oncol 8 (1990) 1543-1555
42. Stroian G., Martens C., Souhami L., Collins D.L., and Seuntjens J. Local correlation between monte-carlo dose and radiation-induced fibrosis in lung cancer patients. Int J Radiat Oncol Biol Phys 70 (2008) 921-930
43. Depierre A., Lagrange J.L., Theobald S., Astoul P., Baldeyrou P., Bardet E., et al. Standards, Options and Recommendations for the management of non-small cell lung carcinoma patients. Bull Cancer 90 (2003) 151-166
44. Travis E.L., Parkins C.S., Down J.D., Fowler J.F., and Thames Jr. H.D. Repair in mouse lung between multiple small doses of X rays. Radiat Res 94 (1983) 326-339
45. Marks L.B. The pulmonary effects of thoracic irradiation. Oncology 8 (1994) 89-106
46. Wiernik G. Radiation pneumonitis following a low dose of Cobalt teletherapy. Br J Radiol 38 (1965) 314
47. Logan P.M. Thoracic manifestations of external beam radiotherapy. AJR Am J Roentgenol 171 (1998) 569-577
48. Oetzel D., Schraube P., Hensley F., Sroka-Perez G., Menke M., and Flentje M. Estimation of pneumonitis risk in three-dimensional treatment planning using dose-volume histogram analysis. Int J Radiat Oncol Biol Phys 33 (1995) 455-460
49. Kwa S.L., Lebesque J.V., Theuws J.C., Marks L.B., Munley M.T., Bentel G., et al. Radiation pneumonitis as a function of mean lung dose: an analysis of pooled data of 540 patients. Int J Radiat Oncol Biol Phys 42 (1998) 1-9
50. Lyman J.T. Complication probability as assessed from dose-volume histograms. Radiat Res Suppl 8 (1985) S13-S19
51. Kutcher G.J., and Burman C. Calculation of complication probability factors for non-uniform normal tissue irradiation: the effective volume method. Int J Radiat Oncol Biol Phys 16 (1989) 1623-1630
52. Lyman J.T., and Wolbarst A.B. Optimization of radiation therapy. IV: a dose-volume histogram reduction algorithm. Int J Radiat Oncol Biol Phys 17 (1989) 433-436
53. Withers H.R., Taylor J.M., and Maciejewski B. Treatment volume and tissue tolerance. Int J Radiat Oncol Biol Phys 14 (1988) 751-759
54. Martel M.K., Ten Haken R.K., Hazuka M.B., Turrisi A.T., Fraass B.A., and Lichter A.S. Dose-volume histogram and 3-D treatment planning evaluation of patients with pneumonitis. Int J Radiat Oncol Biol Phys 28 (1994) 575-581
55. Rodrigues G., Lock M., D'Souza D., Yu E., and Van Dyk J. Prediction of radiation pneumonitis by dose-volume histogram parameters in lung cancer--a systematic review. Radiother Oncol 71 (2004) 127-138
56. Rubin P., Johnston C.J., Williams J.P., McDonald S., and Finkelstein J.N. A perpetual cascade of cytokines postirradiation leads to pulmonary fibrosis. Int J Radiat Oncol Biol Phys 33 (1995) 99-109
57. Madani I., De Ruyck K., Goeminne H., De Neve W., Thierens H., and Van Meerbeeck J. Predicting risk of radiation-induced lung injury. J Thorac Oncol 2 (2007) 864-874
58. Arpin D., Perol D., Blay J.Y., Falchero L., Claude L., Vuillermoz-Blas S., et al. Early variations of circulating interleukin-6 and interleukin-10 levels during thoracic radiotherapy are predictive for radiation pneumonitis. J Clin Oncol 23 (2005) 8748-8756
59. Chen Y., Rubin P., Williams J., Hernady E., Smudzin T., and Okunieff P. Circulating IL-6 as a predictor of radiation pneumonitis. Int J Radiat Oncol Biol Phys 49 (2001) 641-648
60. Hart J.P., Broadwater G., Rabbani Z., Moeller B.J., Clough R., Huang D., et al. Cytokine profiling for prediction of symptomatic radiation-induced lung injury. Int J Radiat Oncol Biol Phys 63 (2005) 1448-1454
61. Anscher M.S., Kong F.M., Marks L.B., Bentel G.C., and Jirtle R.L. Changes in plasma transforming growth factor beta during radiotherapy and the risk of symptomatic radiation-induced pneumonitis. Int J Radiat Oncol Biol Phys 37 (1997) 253-258
62. Anscher M.S., Kong F.M., Andrews K., Clough R., Marks L.B., Bentel G., et al. Plasma transforming growth factor beta1 as a predictor of radiation pneumonitis. Int J Radiat Oncol Biol Phys 41 (1998) 1029-1035
63. Anscher M.S., Marks L.B., Shafman T.D., Clough R., Huang H., Tisch A., et al. Risk of long-term complications after TFG-beta1-guided very-high-dose thoracic radiotherapy. Int J Radiat Oncol Biol Phys 56 (2003) 988-995
64. Ishii Y., and Kitamura S. Soluble intercellular adhesion molecule-1 as an early detection marker for radiation pneumonitis. Eur Respir J 13 (1999) 733-738
65. Barthelemy-Brichant N., Bosquee L., Cataldo D., Corhay J.L., Gustin M., Seidel L., et al. Increased IL-6 and TGF-beta1 concentrations in bronchoalveolar lavage fluid associated with thoracic radiotherapy. Int J Radiat Oncol Biol Phys 58 (2004) 758-767
66. Chen Y., Williams J., Ding I., Hernady E., Liu W., Smudzin T., et al. Radiation pneumonitis and early circulatory cytokine markers. Semin Radiat Oncol 12 (2002) 26-33
67. De Jaeger K., Seppenwoolde Y., Kampinga H.H., Boersma L.J., Belderbos J.S., and Lebesque J.V. Significance of plasma transforming growth factor-beta levels in radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 58 (2004) 1378-1387
68. Franko A.J., Sharplin J., Ward W.F., and Hinz J.M. The genetic basis of strain-dependent differences in the early phase of radiation injury in mouse lung. Radiat Res 126 (1991) 349-356
69. Kong F.M., Anscher M.S., Sporn T.A., Washington M.K., Clough R., Barcellos-Hoff M.H., et al. Loss of heterozygosity at the mannose 6-phosphate insulin-like growth factor 2 receptor (M6P/IGF2R) locus predisposes patients to radiation-induced lung injury. Int J Radiat Oncol Biol Phys 49 (2001) 35-41